Last 48 quarters of trend data · Healthcare · Big Pharma
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 13.80 | 14.86 | 8.89 | 11.57 | 25.44 | 10.44 | 18.08 | 12.71 | 400.57 | 21.56 | 12.51 | — | 14.74 | 15.60 | 16.15 | 16.19 | 18.93 | 23.70 | 29.17 | 30.94 | 14.57 |
| — | +42.3% | -50.8% | -8.9% | -93.6% | -51.6% | +44.6% | — | +2616.8% | +38.2% | -22.5% | — | -22.1% | -34.2% | -44.6% | -47.7% | +30.0% | +10.5% | -17.9% | +74.5% | — | |
| P/S Ratio | 2.54 | 2.45 | 2.27 | 2.70 | 2.20 | 1.88 | 1.92 | 2.77 | 2.33 | 2.21 | 1.73 | 2.31 | 2.27 | 2.73 | 2.99 | 3.23 | 3.35 | 3.40 | 3.48 | 3.39 | 2.89 |
| — | +30.3% | +18.3% | -2.7% | -5.7% | -14.9% | +11.3% | +20.0% | +2.7% | -19.1% | -42.3% | -28.4% | -32.2% | -19.7% | -14.0% | -4.8% | +16.1% | +19.2% | +8.3% | +5.1% | -8.5% | |
| P/B Ratio | 6.85 | 5.47 | 5.29 | 6.17 | 5.95 | 4.94 | 5.39 | 7.12 | 7.03 | 6.11 | 4.94 | 6.63 | 3.54 | 4.12 | 4.20 | 4.59 | 4.91 | 4.66 | 5.07 | 4.99 | 3.84 |
| — | +10.8% | -2.0% | -13.4% | -15.4% | -19.1% | +9.3% | +7.4% | +98.7% | +48.2% | +17.6% | +44.3% | -28.0% | -11.6% | -17.2% | -8.0% | +27.8% | +31.0% | +24.1% | +31.6% | +4.2% | |
| P/FCF | 13.67 | 8.35 | 9.55 | 40.93 | 17.16 | 3.84 | 6.63 | 18.33 | 7.09 | 4.99 | 10.21 | 10.76 | 6.65 | 6.79 | 20.64 | 13.60 | 12.91 | 11.10 | 20.80 | 11.10 | 9.26 |
| — | +117.6% | +44.0% | +123.2% | +141.9% | -23.1% | -35.0% | +70.5% | +6.7% | -26.6% | -50.6% | -20.9% | -48.5% | -38.8% | -0.8% | +22.5% | +39.5% | +67.1% | +57.6% | +13.4% | -10.2% | |
| EV / EBITDA | 10.70 | 13.89 | 8.25 | 10.15 | 9.70 | 6.84 | 6.93 | 9.13 | 16.32 | 7.80 | 7.70 | 9.70 | 7.60 | 8.35 | 9.44 | 9.06 | 10.89 | 9.60 | 9.38 | 9.05 | 8.83 |
| — | +103.1% | +19.0% | +11.3% | -40.6% | -12.3% | -9.9% | -5.9% | +114.7% | -6.6% | -18.5% | +7.1% | -30.2% | -13.1% | +0.7% | +0.1% | +23.3% | +3.8% | -13.8% | -1.8% | -31.7% | |
| EV / EBIT | 11.94 | 13.89 | 8.48 | 11.01 | 19.32 | 8.85 | 14.69 | 11.88 | 58.15 | 17.03 | 18.26 | — | 16.87 | 15.79 | 19.30 | 14.46 | 21.41 | 18.45 | 21.77 | 23.80 | 19.48 |
| — | +57.0% | -42.3% | -7.3% | -66.8% | -48.0% | -19.6% | — | +244.6% | +7.9% | -5.4% | — | -21.2% | -14.4% | -11.3% | -39.3% | +9.9% | +11.1% | -11.7% | +53.1% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.1% | 68.3% | 71.3% | 70.2% | 67.2% | 71.9% | 72.5% | 72.9% | 61.0% | 75.1% | 73.2% | 55.5% | 56.6% | 56.7% | 54.6% | 57.5% | 56.9% | 57.5% | 57.1% | 58.0% | 60.0% |
| — | -5.0% | -1.7% | -3.7% | +10.2% | -4.3% | -1.0% | +31.3% | +7.9% | +32.5% | +34.1% | -3.4% | -0.6% | -1.3% | -4.5% | -1.0% | -5.2% | -1.3% | -0.3% | +5.6% | +6.5% | |
| Operating Margin | 28.5% | 21.8% | 31.0% | 29.3% | 22.5% | 29.8% | 30.8% | 31.2% | 4.1% | 18.3% | 13.9% | 12.9% | 17.0% | 19.2% | 17.3% | 21.6% | 15.0% | 19.9% | 22.6% | 23.3% | 18.6% |
| — | -26.9% | +0.9% | -6.2% | +444.5% | +63.0% | +121.9% | +141.3% | -75.7% | -4.8% | -19.9% | -40.2% | +13.2% | -3.5% | -23.5% | -7.0% | -19.4% | +33.4% | +69.9% | +17.3% | +182.2% | |
| Net Margin | 14.6% | 16.5% | 25.6% | 23.3% | 8.7% | 18.0% | 10.7% | 21.9% | 0.6% | 10.2% | 13.8% | -100.4% | 15.4% | 17.6% | 18.5% | 20.0% | 17.7% | 14.3% | 12.0% | 11.0% | 19.8% |
| — | -8.1% | +139.5% | +6.3% | +1390.2% | +76.8% | -22.5% | +121.8% | -96.2% | -42.1% | -25.4% | -603.1% | -13.4% | +22.8% | +54.5% | +81.9% | -10.4% | +7.6% | +32.6% | -39.9% | +121.8% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 40.4% | 9.5% | 15.6% | 13.9% | 5.9% | 12.2% | 7.5% | 14.5% | 0.4% | 7.1% | 10.0% | -51.7% | 6.0% | 6.3% | 6.5% | 7.2% | 6.3% | 4.9% | 4.4% | 3.8% | 6.5% |
| — | -22.5% | +108.5% | -4.5% | +1266.7% | +72.6% | -25.0% | +128.1% | -92.9% | +12.0% | +54.1% | -820.7% | -5.0% | +28.5% | +46.8% | +90.1% | -2.2% | +17.8% | +56.1% | -29.4% | +128.4% | |
| ROA | 7.7% | 2.5% | 3.8% | 3.0% | 1.2% | 2.3% | 1.4% | 2.7% | 0.1% | 1.3% | 1.7% | -12.3% | 1.9% | 2.1% | 2.2% | 2.4% | 2.1% | 1.6% | 1.4% | 1.2% | 2.2% |
| — | +6.7% | +172.1% | +14.3% | +1404.5% | +78.7% | -19.3% | +121.6% | -95.9% | -38.4% | -21.4% | -618.2% | -8.8% | +29.0% | +58.0% | +96.7% | -3.7% | +16.0% | +47.8% | -31.2% | +126.2% | |
| ROIC | 18.3% | 3.7% | 5.3% | 4.5% | 3.9% | 5.0% | 5.0% | 4.6% | 0.6% | 2.6% | 2.0% | 1.9% | 2.4% | 2.6% | 2.3% | 2.9% | 2.0% | 2.6% | 3.1% | 3.1% | 2.4% |
| — | -25.7% | +6.6% | -1.5% | +494.9% | +91.6% | +154.2% | +145.8% | -73.4% | +1.7% | -15.9% | -37.0% | +21.0% | -0.8% | -24.8% | -3.8% | -17.6% | +40.3% | +93.6% | +38.3% | +237.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.55 | 1.91 | 1.93 | 2.31 | 2.55 | 2.74 | 2.91 | 2.94 | 3.12 | 2.99 | 3.16 | 3.47 | 1.41 | 1.35 | 1.22 | 1.23 | 1.31 | 1.23 | 1.32 | 1.45 | 1.27 |
| — | -30.2% | -33.7% | -21.4% | -18.5% | -8.2% | -8.0% | -15.4% | +122.2% | +121.2% | +158.6% | +181.0% | +7.5% | +10.3% | -7.2% | -15.0% | +3.3% | -0.3% | +5.0% | +15.8% | -7.2% | |
| Debt / EBITDA | 2.66 | 15.25 | 9.34 | 11.73 | 12.44 | 10.98 | 10.64 | 11.36 | 21.42 | 10.79 | 12.60 | 14.12 | 9.39 | 8.65 | 8.96 | 8.06 | 9.61 | 8.33 | 8.16 | 8.69 | 9.47 |
| — | +38.9% | -12.3% | +3.2% | -41.9% | +1.7% | -15.5% | -19.5% | +128.2% | +24.7% | +40.6% | +75.0% | -2.3% | +3.9% | +9.7% | -7.2% | +1.5% | -19.0% | -24.7% | -10.6% | -37.3% | |
| Current Ratio | 1.26 | 1.59 | 1.53 | 1.42 | 1.26 | 1.27 | 1.21 | 1.28 | 1.25 | 1.24 | 1.16 | 1.11 | 1.43 | 1.18 | 1.39 | 1.42 | 1.25 | 1.42 | 1.44 | 1.32 | 1.52 |
| — | +25.3% | +26.9% | +11.0% | +0.2% | +2.1% | +4.4% | +15.2% | -12.2% | +5.3% | -17.0% | -21.8% | +14.5% | -16.8% | -3.5% | +7.5% | -18.1% | -3.4% | -6.0% | -15.6% | -3.9% | |
| Quick Ratio | 1.14 | 1.44 | 1.38 | 1.28 | 1.14 | 1.17 | 1.11 | 1.17 | 1.15 | 1.09 | 1.02 | 0.99 | 1.31 | 1.07 | 1.28 | 1.28 | 1.14 | 1.31 | 1.34 | 1.23 | 1.43 |
| — | +23.5% | +25.1% | +9.3% | -0.4% | +6.9% | +8.2% | +17.4% | -12.4% | +1.8% | -19.8% | -22.5% | +14.8% | -17.8% | -4.8% | +4.5% | -20.1% | -4.3% | -5.8% | -15.4% | -3.3% | |
| Interest Coverage | 5.93 | 7.29 | 11.04 | 8.88 | 4.40 | 7.49 | 4.66 | 7.01 | 1.35 | 4.32 | 3.47 | -26.10 | 6.30 | 8.57 | 7.59 | 10.62 | 7.32 | 8.39 | 7.26 | 6.17 | 6.75 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BMY stock.
Bristol-Myers Squibb Company's current P/E is 13.8x. The average P/E over the last 4 quarters is 15.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Bristol-Myers Squibb Company's current operating margin is 28.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bristol-Myers Squibb Company's business trajectory between earnings reports.